The Evolving Role of Subcutaneous Therapies in NSCLC

home / peer-exchange / the-evolving-role-of-subcutaneous-therapies-in-nsclc

Panel of experts will explore treatment of EGFR + NSCLC. Panelists discuss efficacy and safety data from recent studies and how these data are shaping EGFR+ NSCLC management in clinical practice. Panelists also talk about increasing interest in the use of subcutaneous formulations of NSCLC treatments and how this mode of administration can advance patient care in EGFR+ NSCLC.

EP. 1: Understanding EGFR Mutations and First-Line Treatment

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

October 23rd 2025

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.

Watch

EP. 2: Overcoming Resistance Mechanisms and Addressing Unmet Needs

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

October 23rd 2025

Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.

Watch

EP. 3: Impact of Recent Approvals and Novel Mechanisms

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

October 30th 2025

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Watch

EP. 4: CNS Penetration and Efficacy of Emerging Therapies

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

October 30th 2025

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Watch

EP. 5: Managing Adverse Events and Integrating Amivantamab Plus Lazertinib

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

November 6th 2025

Panelists discuss how proactive AE management optimizes safety and adherence with emerging EGFR-targeted regimens.

Watch

EP. 6: Sequencing Therapies and Using the Most Effective Options First

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

November 6th 2025

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes.

Watch

EP. 7: The Value of Subcutaneous Therapy for Patients

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

November 13th 2025

Panelists discuss how SC delivery enhances patient convenience and health care efficiency in NSCLC treatment.

Watch

EP. 8: FDA Approvals, Patient Selection, and SC Amivantamab

Jorge Garcia, PharmD, MS, MHA, MBA, FACHE;Joshua K. Sabari, MD;Amanda Cass, PharmD, BCPS, BCOP; Tammy McClellan, PharmD;Fawzi F Abu Rous, MD

November 13th 2025

Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.

Watch

EP. 9: Counseling Patients on IV vs SC Administration